ArticleProceedings of the National Academy of Sciences of the United States of America2018
LSD1: A single target to combat lineage plasticity in lethal prostate cancer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer.Molecular oncology · 2026Article
- Review
- A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer.Oncogene · 2025Article
- Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.BMC cancer · 2024Article
- Treatment-induced stemness and lineage plasticity in driving prostate cancer therapy resistance.Cancer heterogeneity and plasticity · 2024Article
- Review
- [Expression pattern of the histone lysine demethylase family and its potential role in bladder cancer: a multi-omics analysis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Epigenetic reprogramming during prostate cancer progression: A perspective from development.Seminars in cancer biology · 2022Review
- OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer.Scientific reports · 2022Article
- Histone Methylases and Demethylases Regulating Antagonistic Methyl Marks: Changes Occurring in Cancer.Cells · 2022Review
- Narrative review of challenges in the management of advanced neuroendocrine prostate cancer.Translational andrology and urology · 2021Review
- Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.JCI insight · 2021Article
- Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment.Biomedicines · 2021Review
- TwoFrontiers in plant science · 2021Article
- LSD1/KDM1A inhibitors in clinical trials: advances and prospects.Journal of hematology & oncology · 2019Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.